GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Synergy Pharmaceuticals Inc (SGYP) [hlAlert]

Rating:
Buy SGYP
down 0.27 %

Synergy Pharmaceuticals Inc (SGYP) rated Buy with price target $15 by Morgan Joseph

Posted on: Friday,  May 13, 2011  9:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Synergy Pharmaceuticals Inc (NASDAQ: SGYP) on 05/13/2011, when the stock price was $7.40. Since
then, Synergy Pharmaceuticals Inc has lost 0.27% as of 01/05/2016's recent price of $7.38.
If you would have followed this Morgan Joseph's recommendation on SGYP, you would have lost 0.27% of your investment in 1698 days.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company?s lead drug candidate is SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). SP-304 is an analog of uroguanylin, a natural GI hormone secreted in the gut, which is a key regulator of intestinal function. As of December 31, 2009, the Company was developing SP-304, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. SP-304 is an agonist of GC-C. In February, 2010, a Phase IIa 14-day, repeated-oral-dose trial of SP-304 in CC patients opened for enrollment and was actively recruiting patients.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/13/2011 9:25 AM Buy
None
7.40 30.00
as of 12/30/2011
1 Week down  -5.13 %
1 Month down  -19.86 %
3 Months down  -45.15 %
1 YTD down  -52.56 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy